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Abstract
Valproate (VPA) is a highly effective drug successfully employed in several neuropsychiatric diseases. In the last 15 years, an
increased prevalence of polycystic ovary syndrome (PCOS) associated with VPA use has been reported in both women with
epilepsy and women with bipolar disorders. However, data on this subject are contrasting and it is possible that different
factors might play a role in the development of PCOS in these patients. The risk of developing PCOS during VPA treatment
seems to be higher in women with epilepsy than in women with bipolar disorders, and this might be due to an underlying
neuroendocrine dysfunction related to the seizure disorder. Gynecologists must be aware of the possibility that PCOS in
these populations of patients might be related to VPA use, and a careful multi-specialist approach is required for evaluating
the risks and benefits of this treatment in the presence of features of PCOS.
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Introduction
Polycystic ovary syndrome (PCOS) is one of the most
common endocrine disorders in women of fertile age
[1] and has been considered the most common cause
of oligo-ovulatory infertility [2]. Patients with PCOS
are at higher risk for developing infertility and
endometrial carcinoma, besides several metabolic
disorders including insulin resistance, diabetes melli-
tus, hypertension, dyslipidemia and cardiovascular
disease [3,4]. Despite the vast amount of clinical,
laboratory and experimental data that have been
accumulated, the pathogenesis of PCOS remains a
subject of speculation [5], with both genetic and
environmental factors being implicated [6].
While the ‘classical’ syndrome is usually easily
recognized in women displaying hyperandrogenism,
irregular menstruations, obesity and a polycystic
ovarian morphology, the diagnosis of PCOS in
women who present with fewer of the classical
symptoms has caused considerable controversy [7].
Many efforts were devoted in the last 20 years to reach
uniformity in the diagnostic criteria, since the use of a
standardized definition of PCOS is clearly very
important for comparing epidemiological data and
treatment outcomes in different studies. Most com-
monly, PCOS is defined according to the proceedings
of an expert conference sponsored by the National
Institutes of Health (NIH) in 1990, which requested
for diagnosis hyperandrogenism and/or hyperandro-
genemia, menstrual dysfunction and exclusion of
known disorders [8]. More recently, another expert
conference held in Rotterdam in 2003 proposed
diagnosis of PCOS – after the exclusion of related
disorders – in the presence of any two of the following:
hyperandrogenism and/or hyperandrogenemia, oligo-
or anovulation, or polycystic ovaries [9]. In essence,
the Rotterdam criteria expanded the NIH criteria,
including in the diagnosis of PCOS also ovulatory
womenwith polycystic ovaries and hyperandrogenism
as well as normoandrogenic oligoanovulatory women
with polycystic ovaries. At the present time, several
authors underline that the metabolic and possibly the
reproductive implications of the two additional
phenotypes of PCOS patients proposed by the
Rotterdam criteria are unclear and relatively poorly
characterized [10,11]. For this reason, the Rotterdam
2003 criteria are still debated; modification of the
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NIH 1990 criteria is strongly proposed, but the NIH
criteria are still widely accepted and usually employed
in papers dealing with the diagnosis and epidemiology
of PCOS. It is worth noticing that the most recent
reports on PCOS prevalence in premenopausal
women, obtained following the NIH criteria for
diagnosis, describe remarkably similar values, with a
prevalence of 6.6% in the USA [12], 6.5% in Spain
[13] and 6.8% in Greece [14].
Valproate (VPA) is one of the most commonly used
antiepileptic drugs throughout the world, being a drug
of first choice in many seizure types. Besides to being
an effective drug in the treatment of epilepsy, VPA is
also used by psychiatrists for the treatment of bipolar
disorders, and several reports suggest that this
medication is becoming a widespread therapy for
these conditions, both in the acute and in the long-
term treatment, in adult and in child/adolescent
populations.
Concern about the use of VPA in women has been
spreading after reports suggesting the possibility that
this drug might give rise to reproductive endocrine
disturbances. In fact, in the last 15 years several
reports have suggested that chronic use of VPA in
women might be associated with an increased
frequency of menstrual disorders and/or polycystic
ovaries and/or hyperandrogenism, realizing in some
cases a clear-cut picture of PCOS. These findings,
first reported in women with epilepsy and more
recently also described in females with bipolar
disorders, have received growing attention and raised
concern among neurologists and psychiatrists. The
possibility that an effective, widely used drug may give
rise to unwanted endocrine side-effects, possibly
evolving into reduced fertility and increased cardio-
vascular risk, actually deserves full consideration also
from endocrinologists and gynecologists.
The present paper briefly examines data from the
literature regarding the association between VPA use
and PCOS in women with epilepsy and with bipolar
disorders.
Polycystic ovary syndrome in women using
valproate: A critical review of the literature
The first warnings of a possible association between
VPA use and menstrual dysfunction came from
several anecdotal reports of individual or small series
of women with epilepsy using VPA, in whom
menstrual disturbances, often disappearing after
discontinuation of the drug, were observed [15–19].
In 1993 Isojarvi and colleagues [20] described an
increased prevalence of polycystic ovaries, hyperan-
drogenism and menstrual irregularities (not necessa-
rily associated in the same patient and, consequently,
not necessarily giving rise to a picture of PCOS) in
women with epilepsy treated with VPA; several
reports from the same group in the subsequent years
confirmed their earlier data (see [21]). At this point,
the possible association between PCOS and VPA
received wide attention from the scientific commu-
nity, and research groups from all over the world
investigated the effect of VPA on the reproductive
endocrine status of women with epilepsy or bipolar
disorders.
Unfortunately, no consistency of diagnostic criter-
ia and diagnostic tools is found in these papers, and
consequently the results are very often difficult to
interpret and virtually impossible to compare. Many
authors still confuse the concept of PCOS with that
of polycystic ovaries; others still invoke a supposed
lack of uniformity of criteria for diagnosis of PCOS as
an excuse to use personal views on this subject,
completely ignoring the results of the 1990 NIH
conference or other authoritative guidelines. The
wide variability observed in the characteristics of the
patient series in the different reports also gives rise to
possible inaccuracies and poor comparability of
results. Moreover, additional problems arise when
dealing with papers evaluating VPA effects in women
with epilepsy, since in epileptic patients a possible
deranging effect of epilepsy itself on the hypothala-
mus leading to neuroendocrine dysfunction has been
suggested by several reports, actually earlier than the
ones suggesting a role of VPA [22–26].
With these limitations in mind, however, some
tentative conclusions can be proposed. In considera-
tion of the possible role played by the epileptic
disease, we now review separately reports dealing
with VPA use in women with epilepsy and in women
with bipolar disorders.
Polycystic ovary syndrome, valproate and epilepsy: A
complex association
Many reports assessing the reproductive endocrine
status in epileptic women and evaluating the occur-
rence of PCOS in these populations can be traced in
the literature [20,22,23,24,27–44], but comparing
the results emerging from these studies is not an easy
task. Apart from the difficulties arising from lack of
consistency in criteria employed for diagnosing
PCOS, the comparative analysis of these reports is
problematic because many authors, even when
performing a complete evaluation of patients, present
the results only as means of hormonal values or as
percentages of abnormal findings observed in differ-
ent subgroups, without giving any information on
individual data which allow to determine the
prevalence of PCOS in the studied sample. In an
earlier review [21] we examined in detail most of the
literature on this subject. In the present paper
therefore we discuss only the results of a comparative
analysis of the literature. Some reports have been
totally or partially left out of this analysis for several
reasons: pre-selection of patients with menstrual
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irregularities [20,27]; insufficient data for diagnosing
PCOS [29]; inconsistencies of methodology
[23,36,40,43]; and evaluation of a population of
adolescent patients [30,41,44], in contrast with the
remaining literature that deals with adult women.
A high occurrence of menstrual dysfunctions in
women with epilepsy has long been reported [45–51]
and this finding is confirmed in most of the recent
literature. With the exception of Murialdo and
associates [29], who report a prevalence of 10.8%,
in all the other series in which such information is
offered [23,24,28,31,33,34,35,37,38,42] the preva-
lence of irregular menstruations, ranging from 21.8%
to 65.0%, is quite higher than the 7% prevalence
described in the general population in a recent
epidemiological study [52]. Menstrual irregularities
are observed also in drug-free epileptic patients; in
treated patients it does not seem related to the use of
VPA, since in most reports the distribution of
menstrual irregularities is quite similar in different
therapy groups.
Individual data on hyperandrogenism are more
rarely given [23,24,33–35,37,38,42] and only in
some of these reports [23,24,33–35,42] are labora-
tory data offered. In these latter, hyperandrogenism
is usually over-represented, with a single report
describing a 4.5% prevalence [35] and the others a
prevalence ranging from 15.0% to 26.0% [23,24,33,
34,42]. When a comparison among VPA users
and non-VPA users is performed [24,33–35,
37,38,41,42,44], the prevalence of hyperan-
drogenism is higher in VPA patients in most
reports [34,35,37,38,41,42,44] even if not always
significantly.
Finally, a high prevalence of polycystic ovaries
(430%) is reported in half of the studies [32–
34,39,42] in which this finding was systematically
evaluated, most of which employed transvaginal
scanning or magnetic resonance imaging rather than
transabdominal scanning which is associated with a
lower prevalence [24,28,29,37,38]. Most reports
describe a higher, but not significant, prevalence of
polycystic ovaries in non-VPA users [24,29,32,
37,38,42].
While, even with the caution due to methodologi-
cal differences in the collection and analysis of data,
it is altogether possible to compare the prevalence of
findings such as menstrual dysfunction, hyperandro-
genism and polycystic ovaries in different series of
women with epilepsy, comparing the prevalence of
PCOS in such reports is much more difficult due to
the methodological issues underlined above. If we
consider only reports in which PCOS in patients with
epilepsy is diagnosed, or may be diagnosed employ-
ing available data using the NIH criteria [22–
24,28,33–35,42], we notice in most of these series
that the prevalence of PCOS in epileptic females is
higher than the 6.6% prevalence reported in the
general population with the same diagnostic criteria.
Only in the report from Stephen and co-workers [35]
is a considerably low prevalence of PCOS (2.3%)
observed in epileptic females (a certain degree of
underestimation could derive from lack of evaluation
of clinical features of hyperandrogenism). In the
other reports, the prevalence (often corrected ac-
cording to NIH guidelines) is 12.5% [34], 15%
[22,24,28], 20% [23,42] and 26% [33]. It must be
stressed that the highest prevalence of 26% is
reported in a study in which the endocrine evaluation
of patients with epilepsy is particularly accurate [33],
including assessment not only of menstrual cyclicity
but of ovulation status as well, and evaluation of both
clinical and laboratory hyperandrogenism. The in-
fluence of VPA use on PCOS prevalence is difficult
to evaluate if we consider only the reports in which a
NIH diagnosis can be obtained, due to the small
number of observations; widening our analysis to all
reports [24,31–35,37–39] in which the prevalence of
PCOS is given, even if with different criteria, and in
which a comparison among therapy groups is carried
out, we observe that most reports dealing with
epileptic women describe a higher prevalence of
PCOS in VPA-treated patients [32,34,35,37,39],
even if this finding is statistically significant only in
two reports [34,39].
In summary, we can conclude that in women with
epilepsy the increased prevalence of menstrual
disturbances and of polycystic ovaries do not seem
associated with the use of any antiepileptic drug and
might more probably be related to the epileptic
disorder per se. On the other hand, the finding of
hyperandrogenism is more often related to the use of
VPA. The prevalence of PCOS (NIH-defined) in
women with epilepsy is elevated in the majority of
reports, even if with a considerable variability among
series. The association of PCOS (in this case, also
when diagnosed with non-validated criteria) with
VPA treatment is found in most of the reports
investigating this finding.
Polycystic ovary syndrome related to valproate use in
women with bipolar disorders
In recent years the possible effect of chronic VPA use
has been evaluated also in women receiving this drug
for bipolar disorders. Reports dealing with this
subject are relatively few when compared with those
devoted to the endocrine status of epileptic females
under VPA treatment. However, reports on bipolar
patients have the advantage of studying a population
of VPA users in which the potential influence of
epilepsy has been removed.
Rasgon and collaborators [53] evaluated the
endocrine status of 80 bipolar women, comparing
subjects treated with VPA (alone or in association)
with subjects treated with other antimanic agents.
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PCOS was found in 8% of VPA users and in 0% in
non-VPA users: this difference was not statistically
significant, possibly because of limited statistical
power. The same group [54] successively reported
a 2-year longitudinal evaluation in 25 women with
bipolar disorder, treated with VPA, lithium or
atypical antipsychotics, and described high rates of
menstrual abnormalities, hyperandrogenemia and
insulin resistance in the whole group. Valproate use
was associated with an increase in total testosterone
over time, but rates of oligomenorrhea and clinical
hyperandrogenism did not differ between medication
groups.
Joffe and co-workers [55] evaluated 230 women
with bipolar disorder, comparing the incidence of
oligo-/amenorrhea with hyperandrogenism that de-
veloped after antimanic treatment. Before treatment
the prevalence of PCOS in the whole group was
similar to that reported in the general population
(4.7%). After treatment was started, oligo-/amenor-
rhea with hyperandrogenism developed in nine
(10.5%) of 86 women on valproate and in two
(1.4%) of 144 women on other treatments
(p¼ 0.002), suggesting a significant association of
PCOS with VPA use in bipolar women. In a
subsequent study [56] the authors performed a
follow-up evaluation in nine women who had
developed PCOS while taking VPA, four of whom
had discontinued the drug after developing PCOS
features. This study showed that reproductive
features of PCOS, such as menstrual irregularities
and hyperandrogenism, improved in three out of
four of VPA discontinuers, in spite of unchanged
body weight. Since these results support that VPA
use is associated with new-onset PCOS in women
with bipolar disorders, the authors suggest that this
may be the case also in women with epilepsy,
attributing the higher prevalence of PCOS described
in epileptic patients to the lack of accepted criteria
for the diagnosis of PCOS in reports describing
these latter subjects. However, Joffe’s report is
specifically focused on patients with new-onset of
PCOS symptoms developed after medication use,
and consequently reports incidence of PCOS rather
than prevalence. Consequently, caution must be
employed in comparing the results from this
study with those coming from studies describing
prevalence.
Other studies on bipolar women receiving VPA
[57–59] contrast with the results of Rasgon’s group
[53] and Joffe’s group [55], since they describe a
considerably higher prevalence of PCOS in VPA
users with bipolar disorders. We do not review the
data coming from the reports of O’Donovan and
colleagues [57,58], since they present several short-
comings which warrant caution in the interpretation
of results (for a detailed analysis, see [21,60]).
The report from McIntyre and associates [59],
describing 38 bipolar female patients treated with
VPA or lithium, shows a very high prevalence of
PCOS in bipolar patients, especially in VPA users
(39%) but with high values also in the lithium group
(19%), with a non-significant difference between
groups. However, this study presents some
problems in methods (poor definition of menstrual
irregularities, lack of evaluation of clinical hyper-
androgenism) which might be of concern in evaluat-
ing PCOS prevalence in the different treatment
groups.
In conclusion, bipolar patients seem to show an
increased risk of developing PCOS when treated with
VPA in respect to other antimanic medications.
However, in reports evaluating large series of women
with validated diagnostic criteria, the prevalence of
PCOS in VPA-treated bipolar patients is not much
higher than what is reported in the general popula-
tion and quite lower than what is reported in epileptic
populations. The hypothesis of Joffe and co-workers
that the difference between PCOS prevalence in
bipolar and epileptic patients should be attributed to
the lack of validated criteria for PCOS diagnosis in
epileptic populations is interesting. However, in
several studies on epileptic patients in which well
accepted criteria for diagnosis of PCOS have been
employed [22–24,28,33–35,42], the PCOS preva-
lence is quite higher than what is reported in bipolar
patients. In particular, as we have mentioned above,
the study reporting the highest prevalence of NIH-
defined PCOS in epileptic patients (26%) [33]
employed a very careful endocrine evaluation of
subjects. Quite interestingly, in this series PCOS
does not show a significant association with the use of
VPA.
Akdeniz and collaborators [61] compared the
endocrine status of women with epilepsy and women
with bipolar disorder, describing 15 bipolar patients
treated with lithium, 15 bipolar patients treated with
VPA and 15 epileptic patients treated with VPA.
Menstrual irregularities were observed in 46.7% of
VPA-treated epileptic women, 20% of VPA-treated
bipolar women and 0% of lithium-treated bipolar
women. Laboratory hyperandrogenism was observed
in both VPA groups but not in the lithium group;
however, only in women with epilepsy was this
finding associated with hirsutism. The authors
conclude that even if VPA treatment is associated
with raised testosterone levels in both bipolar and
epileptic women, these latter have an increased
susceptibility to develop a clinical endocrine
dysfunction.
One could speculate that the impact of VPA on
endocrine status is not as strong in bipolar patients as
in women with epilepsy, suggesting that these latter
may have additional risk factors leading to the
development of PCOS under the influence of VPA
use [62].
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Valproate and polycystic ovary syndrome:
Possible links
The mechanism of action of VPA is not entirely
clear. It increases synaptosomal g-aminobutyric acid
(GABA) concentrations through activation of the
GABA-synthesizing enzyme glutamic acid decarbox-
ylase and also inhibits GABA catabolism through
inhibition of GABA transaminase and succinic
semialdehyde dehydrogenase. Moreover, VPA also
inhibits excitatory neurotransmission mediated by
aspartic acid, glutamic acid and g-hydroxybutyric
acid, and reduces cellular excitability through mod-
ulation of voltage-dependent sodium currents.
Several theories have been proposed to explain the
possible pathogenic mechanisms of VPA-induced
endocrine disturbances. A significant increase in
body weight has been reported in nearly 40% of cases
during VPA use [63–66], both in adults and children
and without sex-related differences. Apparently, this
phenomenon is not related to VPA oral dosage and is
poorly influenced by dietary changes or physical
exercise, being responsive, conversely, to VPA
discontinuation [65]. The pathogenesis of VPA-
related weight increase is still unclear, and several
possible mechanisms have been proposed, such as
increased appetite [63], changes in catecholamine
response to glucose load [67] and enhanced avail-
ability of long-chain fatty acids as a result of VPA
binding to serum albumin [68]. In their first report
describing VPA-related endocrine dysfunction [20],
Isojarvi and co-workers suggested that weight gain
could be the main pathogenic factor leading to
reproductive endocrine disturbances, proposing that
VPA-induced obesity might lead to insulin resistance
and consequently hyperinsulinemia, resulting in
direct and/or indirect hyperstimulation of the ovaries,
hyperandrogenism and finally in ovarian polycystic
changes. However, further studies from the same
group [34] challenged the theory that VPA-induced
obesity might have a primary role and suggested that
increase of androgen production might be the first
abnormal finding originating from VPA use. Results
coming from VPA discontinuation in bipolar patients
[56], who showed improvement of menstrual reg-
ularity and hyperandrogenism without changes in
body weight, also support this hypothesis.
How could VPA use lead to hyperandrogenism? A
possible effect on gonadotropin release, mediated by
a VPA-induced increase of GABA levels affecting
secretion of gonadotropin-releasing hormone, is
considered unlikely since VPA-treated hyperandro-
genic patients have normal luteinizing hormone (LH)
levels [20]. Alternatively, a direct effect of VPA on
androgen formation has been suggested [20]. Long-
term VPA treatment in female rats has been
associated with a pronounced reduction in estrogen
levels, a marked increase in testosterone to estrogen
ratio and only a minor effect, if any, on gonadotropins
[69], suggesting a direct effect of VPA on peripheral
sex hormone production in the ovary [70]. An
inhibitory effect of VPA on the aromatase complex,
the enzyme system which converts androgens to
estrogens, has also been recently reported [71].
Recently, Nelson-Degrave and associates [72],
testing the activity of VPA on androgen biosynthesis
in ovarian theca cells isolated from follicles of normal
cycling women, reported data suggesting that VPA
may increase ovarian androgen biosynthesis by
inducing changes in chromatin modifications (his-
tone acetylation) that augment transcription of
steroidogenic genes. The same research group [73],
in a subsequent paper in which the gene expression
profiles of untreated normal, VPA-treated normal
and untreated PCOS theca cells were compared,
reported that VPA-induced and PCOS-induced
changes in gene expression were similar, resulting
in enhancement of Akt/PKB signal transduction in
human theca cells. These important data provide the
first biochemical evidence to support a role for VPA
in the genesis of PCOS-like symptoms.
A possible direct effect of VPA on insulin
metabolism, not mediated by increase in weight,
has also been suggested [74,75] as a possible
additional cause leading to endocrine dysfunction
in VPA-treated women with epilepsy. In a study
directed to evaluate the role of insulin in VPA-
related obesity, Pylvanen and co-workers [74]
reported serum insulin levels being higher in VPA-
treated epileptic subjects compared with BMI-
matched controls; this phenomenon was observed
not only in obese but also in lean VPA-treated
subjects. In a subsequent study, the same group [75]
reported fasting hyperinsulinemia and lower fasting
glucose levels in epileptic patients on VPA mono-
therapy: these findings were similar regardless of
whether the patients had gained weight or not during
VPA treatment or whether they were obese or not at
the time of the study. Fasting serum proinsulin and
C-peptide levels did not differ significantly between
patients and controls. The authors conclude that the
changes in insulin metabolism seen in VPA-treated
epileptic subjects are not due to weight gain or
obesity, and that VPA might interfere with insulin
metabolism in the liver, inhibiting insulin degrada-
tion with resulting higher insulin concentrations in
the peripheral circulation and consequently reduced
plasma glucose concentrations. It must be under-
lined that the same authors in earlier reports
[20,27,34] had described results which contrast with
their later view on this issue, reporting a significant
association between hyperinsulinism and obesity in
VPA-treated epileptic females [20,27] or increased
insulin levels only in obese, but not in lean, VPA-
treated women when compared with normal
controls [34].
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Insulin metabolism in VPA-treated epileptic sub-
jects has been evaluated by other groups as well
[41,44,76–79], the majority of which [41,44,77–79]
do not distinguish between obese and lean patients
and evaluate mean values of insulin and body weight
in the whole group of studied patients. While most of
these studies report hyperinsulinism and weight gain
in VPA-treated patients compared with controls
[44,79] or patients treated with other antiepileptic
drugs [77] or in comparison to pre-treatment values
[78], de Vries and collaborators [41] do not report
any difference in body weight, insulin levels and
fasting glucose levels in VPA-treated and untreated
epileptic patients. When obese and lean patients are
examined separately [76], insulin resistance is
described only in obese but not in lean VPA-treated
epileptic females. On the whole, these findings are in
disagreement with those reported recently by Pylva-
nen’s group [74,75] and do rather support the view
that insulin resistance is related to obesity and is
found only when weight gain occurs.
In conclusion, VPA seems to present different
potential adverse effects on metabolism, since it has
been associated, via different and not necessarily
related mechanisms, to weight gain, hyperandrogen-
ism and hyperinsulinemia. As underlined by Joffe and
co-workers [55], obesity and insulin resistance alone,
even if VPA-related, are unlikely to explain the
association of VPA with PCOS, since PCOS is
uncommon in women with obesity or type 2 diabetes.
However, both weight gain and hyperinsulinemia are
associated with an increased cardiovascular risk and
must be considered severe adverse effects indepen-
dently from their association with PCOS. At the
present time, however, while the association between
weight gain and VPA use is well documented, data in
favor of a possible direct effect of VPA on insulin
metabolism come only from a single group, who had
earlier reported contrasting results on this issue. More
studies are needed to clarify the complex subject of
VPA use, insulin metabolism and body weight.
Conclusions
Valproate is a highly effective drug, widely employed
in different neuropsychiatric conditions such as
epilepsy, bipolar disorders, migraine and chronic
neuropathic pain. Women with epilepsy and women
with bipolar disorders are most likely to receive VPA
for prolonged periods of time, often encompassing
most of their reproductive life, and are consequently
particularly at risk for developing reproductive
endocrine disturbances related to VPA use.
On the other hand, when reviewing the studies
regarding the possible effect of VPA on reproductive
functions in these populations of patients, the
possible role of the specific disease must be taken
into consideration. A reduction of fertility, indepen-
dent from marriage rates, and a high prevalence of
menstrual disturbances have been described in
women with epilepsy since 50 years ago, far before
the introduction of VPA in clinical practice. More
recently, a possible role of seizure disorders in
altering the regular function of the hypothalamic–
pituitary–ovary axis has been suggested by reports
describing significant increases in plasma prolactin
and, less consistently, gonadotropins after epileptic
seizures, which are suggested to result from spread-
ing of paroxysmal discharges within the hypothalamic
areas which control pituitary reproductive hormones
(see [21,62]). Further support to this theory comes
from the evaluation of untreated women with
epilepsy, in whom both an abnormal LH pulsatility
pattern and a significant rise of gonadotropin
secretion during increase of subclinical paroxysmal
activity has been reported [25,80].
Our review of the literature devoted to assessing
the endocrine status in women with epilepsy has
showed that, while menstrual disturbances and
polycystic ovaries are over-represented in these
patients independently from the use of VPA,
hyperandrogenism and PCOS are usually more
frequent in epileptic females treated with VPA.
These data might suggest that both the seizure
disorder and the use of VPA could play a role in
the development of PCOS in women with epilepsy
[62]. Due to neurotransmitter dysfunctions and/or to
spreading of paroxysmal activity within the hypotha-
lamus, women with epilepsy seem to have an
increased susceptibility to hypothalamic dysfunction:
as a result of that, a high percentage of these patients
will present with menstrual disorders, and, possibly,
polycystic ovaries. The further possible evolution
towards a definite clinical disease, specifically PCOS,
seems conversely to be often related to the use of
antiepileptic drugs, and in particular of VPA. This
VPA effect is most probably due to its hyperandro-
genic activity, recently demonstrated in vitro on
human theca cells; weight gain, often associated with
VPA use, may also play an additional role.
At the present time studies in bipolar patients
using VPA are considerably fewer. However, two of
them have the advantage of describing large study
populations and of employing validated methods for
diagnosis of PCOS [53,55]. Both these studies show
an increased prevalence of PCOS in bipolar patients
using VPA when compared with patients using other
antimanic medications. However, the prevalence of
PCOS described in VPA-treated bipolar women is
only slightly higher than what is reported in the
general population, and lower than what is reported
in many epileptic populations evaluated with vali-
dated criteria. This could suggest that bipolar
patients lack the specific susceptibility to reproduc-
tive endocrine dysfunction which is present in
epileptic women, and that consequently VPA has a
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weaker impact on their endocrine status. The
available literature on this issue is contradictory,
since while Rasgon and colleagues describe a very
high prevalence of treatment-unrelated menstrual
abnormalities and hyperandrogenism in bipolar
women [53,54], the pre-treatment assessment in
the population described by Joffe and associates does
not seem to show any difference from the general
population [55]. In a recent study, Klipstein and co-
workers [81] screened women diagnosed with PCOS
for the presence of bipolar illness, reporting in this
population a higher rate of bipolar disorder than what
is expected in the general population, independently
from the use of VPA. These results could suggest that
also bipolar women could present with an increased
susceptibility to develop PCOS, independently from
VPA treatment. However, the authors themselves
report several methodological constraints in their
study and warrant caution in the interpretation of
their results.
In conclusion, in spite of several issues still
needing clarification, prolonged use of VPA seems
to be associated with an increased risk of developing
PCOS in predisposed women. The relative weight of
individual predisposition, associated neuropsychia-
tric diseases, duration and doses of VPA treatment
are still to be fully understood. When dealing with
patients with PCOS, the gynecologist must be aware
of this possibility and investigate about the present or
past use of VPA. Patients with PCOS using VPA
must receive a multi-specialist approach and a careful
evaluation about the balance between risk and
benefits of continuing therapy with this highly
effective drug.
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